References

Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors

10.1200/jco.1998.16.11.3537 · 1998 · External reference

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first‐line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study

10.1200/jco.2001.19.8.2282 · 2001 · External reference

Oral capecitabine vs intravenous 5‐fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

10.1038/sj.bjc.6601676 · 2004 · External reference

DPYD variants as predictors of 5‐fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147)

2014 · External reference

Individualized dosing of fluoropyrimidine‐based chemotherapy to prevent severe fluoropyrimidine‐related toxicity: what are the options?

10.1002/cpt.2069 · 2021 · External reference

DPYD genotype‐guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

10.1016/s1470-2045(18)30686-7 · 2018 · External reference

Known variant DPYD alleles do not explain DPD deficiency in cancer patients

10.1097/00008571-200004000-00002 · 2000 · External reference

Predicting Dihydropyrimidine dehydrogenase deficiency and related 5‐fluorouracil toxicity: opportunities and challenges of DPYD exon sequencing and the role of phenotyping assays

10.3390/ijms232213923 · 2022 · External reference

Quantitative contribution of rs75017182 to Dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity

10.1002/cpt.685 · 2017 · External reference

Clinical pharmacogenetics implementation consortium (CPIC) guideline for Dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update

10.1002/cpt.911 · 2018 · External reference

DPYD genotyping recommendations: a joint consensus recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, clinical pharmacogenetics implementation consortium, College of American Pathologists, Dutch pharmacogenetics working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, pharmacogenomics knowledgebase, and Pharmacogene variation consortium

10.1016/j.jmoldx.2024.05.015 · 2024 · External reference

Studies on fluorinated pyrimidines. IX. The degradation of 5‐fluorouracil‐6‐C14

10.1016/s0021-9258(18)69542-0 · 1960 · External reference

Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5‐fluorouracil chemotherapy

1993 · External reference

Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients

10.1038/sj.bjc.6690097 · 1999 · External reference

5‐fluorouracil‐related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency

10.1016/j.canlet.2006.09.006 · 2007 · External reference

Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver

1996 · External reference

Application of simple chromatographic methods for the diagnosis of defects in pyrimidine degradation

10.1093/clinchem/39.3.380 · 1993 · External reference

Predicting 5‐fluorouracil toxicity: DPD genotype and 5,6‐dihydrouracil:uracil ratio

10.2217/pgs.14.126 · 2014 · External reference

Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency

10.1111/bcp.15536 · 2023 · External reference

The Mayo Clinic biobank: a building block for individualized medicine

10.1016/j.mayocp.2013.06.006 · 2013 · External reference

Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: implication for 5‐fluorouracil toxicity

10.1111/bcp.14742 · 2021 · External reference

Novel deleterious Dihydropyrimidine dehydrogenase variants may contribute to 5‐fluorouracil sensitivity in an east African population

10.1002/cpt.531 · 2017 · External reference

Discovering novel germline genetic variants linked to severe fluoropyrimidine‐related toxicity in‐ and outside DPYD

10.1186/s13073-024-01354-z · 2024 · External reference

pTrimmer: an efficient tool to trim primers of multiplex deep sequencing data

10.1186/s12859-019-2854-x · 2019 · External reference

Graph‐based genome alignment and genotyping with HISAT2 and HISAT‐genotype

10.1038/s41587-019-0201-4 · 2019 · External reference

10.1101/201178

10.1101/201178 · External reference

A genomic mutational constraint map using variation in 76,156 human genomes

10.1038/s41586-023-06045-0 · 2024 · External reference

Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity

10.1158/0008-5472.can-13-2482 · 2014 · External reference

Gene‐specific variant classifier (DPYD‐Varifier) to identify deleterious alleles of Dihydropyrimidine dehydrogenase

10.1002/cpt.1020 · 2018 · External reference

Crystal structure of the productive ternary complex of dihydropyrimidine dehydrogenase with NADPH and 5‐iodouracil. Implications for mechanism of inhibition and electron transfer

10.1074/jbc.m111877200 · 2002 · External reference

Fluoropyrimidine‐associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>a: impact of haplotype

10.1007/s00280-022-04491-7 · 2023 · External reference

Age and sex are independent predictors of 5‐fluorouracil toxicity. Analysis of a large scale phase III trial

10.1002/1097-0142(19950101)75:1<11::aid-cncr2820750104>3.0.co;2-n · 1995 · External reference

Women experience greater toxicity with fluorouracil‐based chemotherapy for colorectal cancer

10.1200/jco.2002.20.6.1491 · 2002 · External reference

Differences in toxicity between men and women treated with 5‐fluorouracil therapy for colorectal carcinoma

10.1002/cncr.20878 · 2005 · External reference

The value of dihydrouracil/uracil plasma ratios in predicting 5‐fluorouracil‐related toxicity in colorectal cancer patients

10.1177/147323001003800413 · 2010 · External reference

Can we identify patients carrying targeted deleterious DPYD variants with plasma uracil and dihydrouracil? A GPCO‐RNPGx retrospective analysis

10.1515/cclm-2024-0317 · 2024 · External reference

Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine‐associated toxicity

10.1038/bjc.2017.94 · 2017 · External reference

Unresolved reference

External reference

Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene

10.1016/j.bbadis.2016.01.009 · 2016 · External reference

Unresolved reference

External reference

Dose‐individualisation of fluoropyrimidines based on pre‐treatment serum uracil levels: the Alpe2U study

10.1016/j.ejca.2025.115483 · 2025 · External reference

A comprehensive population‐based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency

10.1038/s41416-020-0962-z · 2020 · External reference

A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity

10.1038/clpt.2013.69 · 2013 · External reference

Haematological and non‐haematological toxicity after 5‐fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex international study group

10.1016/s0959-8049(98)00259-7 · 1998 · External reference

Sex differences in fluorouracil‐induced stomatitis

10.1200/jco.2000.18.2.412 · 2000 · External reference

Severe toxicity related to the 5‐fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients

10.1097/01.coc.0000017526.55135.6d · 2003 · External reference

Effects of gender on capecitabine toxicity in colorectal cancer

10.1177/1078155215587345 · 2016 · External reference

Influence of sex and age on fluorouracil clearance

10.1200/jco.1992.10.7.1171 · 1992 · External reference

Relative importance of dose, body surface area, sex, and age for 5‐fluorouracil clearance

1991 · External reference

Gender‐specific elimination of continuous‐infusional 5‐fluorouracil in patients with gastrointestinal malignancies: results from a prospective population pharmacokinetic study

10.1007/s00280-012-2018-4 · 2013 · External reference